7Baggers

Ikena Oncology, Inc
(NASDAQ:IKNA) 

IKNA stock logo

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced ass...

Founded: 2016
Sector: Healthcare
Industry: Biotechnology
OncologyHealthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
                         
      license revenue
    		                     
      operating expenses:
    		                     
      research and development
    		5,961,000 3,274,000 15,558,000 4,025,000 3,715,000 4,580,000 6,818,000 9,832,000 9,645,000 14,274,000 14,654,000 15,172,000 15,552,000 15,639,000 18,850,000 15,488,000 14,343,000 12,338,000 13,375,000 11,374,000 10,021,000 
      general and administrative
    		6,118,000 5,230,000 11,036,000 4,416,000 5,644,000 7,595,000 4,777,000 5,308,000 5,999,000 8,293,000 6,034,000 5,322,000 5,276,000 4,925,000 5,428,000 5,845,000 6,003,000 5,087,000 4,893,000 4,862,000 3,173,000 
      total operating expenses
    		12,079,000 8,504,000 26,594,000 8,750,000 10,794,000 12,517,000 12,407,000 15,823,000 18,226,000 22,567,000 20,688,000 20,494,000 20,828,000 20,564,000 24,278,000 21,333,000 20,346,000 17,425,000 18,268,000 16,236,000 13,194,000 
      income from operations
    		-12,079,000 -8,504,000 -26,594,000 -8,750,000 -10,794,000 -12,517,000 -12,407,000 -15,823,000 -18,226,000 -21,908,000 -19,503,000 -18,490,000 -15,515,000 -15,114,000 -17,876,000 -20,951,000 -16,962,000 2,792,000 -14,522,000 -12,687,000 -9,720,000 
      yoy
    		11.90% -32.06% 114.35% -44.70% -40.78% -42.87% -36.38% -14.42% 17.47% 44.95% 9.10% -11.75% -8.53% -641.33% 23.10% 65.14% 74.51%     
      qoq
    		42.04% -68.02% 203.93% -18.94% -13.77% 0.89% -21.59% -13.18% -16.81% 12.33% 5.48% 19.17% 2.65% -15.45% -14.68% 23.52% -707.52% -119.23% 14.46% 30.52%  
      other income:
    		                     
      interest income
    		1,129,000 2,444,000 -96,000          730,000 893,000 576,000 507,000 172,000     
      other income
    		341,000 -1,124,000 1,837,000 4,708,000 785,000 1,878,000 412,000 235,000 -7,000    566,000     5,000 7,000 6,000 4,000 
      total other income
    		1,470,000 1,320,000 1,741,000 5,998,000 2,203,000 3,446,000 2,183,000 2,155,000 2,107,000 2,257,000 2,160,000 1,375,000 1,296,000 1,017,000 538,000 460,000 123,000     
      income before income taxes
    		-10,609,000 -7,184,000 -24,853,000 -2,752,000 -8,591,000 -9,071,000 -10,224,000 -13,668,000 -16,119,000             
      income tax expense
    		-10,000   -15,000 -28,000 -24,750 -10,000 -62,000 -27,000             
      net income
    		-10,619,000 -6,908,000 -24,779,000 -2,767,000 -8,619,000 -9,124,000 -10,234,000 -13,730,000 -16,146,000 -19,489,000 -17,343,000 -17,115,000 -14,219,000 -14,097,000 -17,338,000 -20,491,000 -16,839,000     
      yoy
    		23.20% -24.29% 142.12% -79.85% -46.62% -53.18% -40.99% -19.78% 13.55% 38.25% 0.03% -16.48% -15.56%         
      qoq
    		53.72% -72.12% 795.52% -67.90% -5.53% -10.85% -25.46% -14.96% -17.15% 12.37% 1.33% 20.37% 0.87% -18.69% -15.39% 21.69%      
      accretion of redeemable convertible preferred shares
    		 14,092,000 -846,000                   
      net loss attributable to common stockholders
    		-10,619,000 -6,908,000 -25,625,000                   
      net loss per common share, basic and diluted
    		-950                     
      weighted-average common shares outstanding, basic and diluted
    		11,211,268,000   48,258,111 48,258,111 48,258,111 48,258,111 48,258,111 48,258,111 41,735,081    36,188,420        
      comprehensive loss:
    		                     
      other comprehensive income:
    		                     
      unrealized loss on marketable securities
    		-104,000   -34,000          418,000 -77,000 -626,000 -478,000     
      foreign currency translation adjustment
    		  -3                   
      total comprehensive loss
    		-10,723,000 -6,915 -24,688 -2,801,000 -8,588,000 -9,296,000 -9,644,000 -13,767,000 -16,411,000 -18,484,000 -17,177,000 -17,080,000 -13,947,000 -68,347,000 -77,000 -626,000 -478,000     
      income tax benefit
    		 424,000 -74,000                   
      loss per share – basic and diluted:
    		                     
      common stock
    		 0.34 -2.91                   
      series a convertible preferred shares
    		 0.34 -2.91                   
      weighted-average shares used for eps calculation
    		                     
      other comprehensive loss:
    		                     
      unrealized gain on marketable securities
    		 -7 94  31,000 -172,000 590,000 -37,000 -265,000 1,005,000 166,000 35,000 272,000         
      restructuring and other charges
    		   309,000 1,435,000 342,000 812,000 683,000 2,582,000             
      investment income
    		   1,290,000 1,418,000 1,568,000 1,771,000 1,920,000 2,114,000 2,271,000 2,162,000 1,381,000          
      net income per share
    		   -0.06 -0.18 -0.19 -0.21 -0.28 -0.33 -0.4 -0.4 -0.44 -0.39 -0.39 -0.48 -0.57 -0.47 0.24 -0.4 -0.35 -2.52 
      collaboration revenue
    		                     
      statement of operations
    		                     
      research and development revenue under collaboration agreement
    		         659,000 1,185,000 2,004,000 5,313,000 5,450,000 6,402,000 382,000 3,384,000 20,217,000 3,746,000 3,549,000 3,474,000 
      other expense
    		         -14,000 -2,000 -6,000  124,000 -38,000 -47,000 -49,000     
      weighted-average common stock outstanding, basic and diluted
    		          43,437,844 39,292,710 36,257,493         
      weighted-average common stocks outstanding, basic and diluted
    		              36,257,074 36,160,951 36,075,407  35,860,284 35,853,341 3,850,264 
      net loss and comprehensive loss
    		                 2,797,000 -14,515,000 -12,681,000 -9,716,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
                          
        assets
      		                    
        current assets:
      		                    
        cash and cash equivalents
      		94,532,000 103,162,000 58,290,000 36,763,000 39,393,000 45,190,000 44,268,000 52,852,000 119,894,000 121,277,000 70,868,000 29,329,000 59,919,000 67,074,000 48,487,000 46,877,000 232,217,000 245,899,000 264,004,000 281,010,000 
        marketable securities
      		40,817,000 39,421,000 37,352,000 77,288,000 84,993,000 92,843,000 101,151,000 104,497,000 55,571,000 75,656,000 86,444,000 108,484,000 97,028,000 107,287,000 144,323,000 165,498,000     
        prepaid expenses and other current assets
      		4,939,000 4,949,000 3,371,000 2,948,000 2,783,000 3,500,000 3,902,000 3,817,000 3,197,000 3,701,000 3,334,000 3,365,000 3,063,000 3,617,000 6,335,000 3,675,000 4,299,000 5,966,000 4,706,000 2,224,000 
        total current assets
      		140,288,000 147,532,000 99,013,000 116,999,000 127,169,000 141,533,000 149,321,000 161,166,000 178,662,000 200,634,000 160,646,000 141,178,000 160,010,000 177,978,000 199,145,000 216,050,000 236,516,000 251,865,000 268,710,000 283,234,000 
        non-current assets:
      		                    
        operating lease right-of-use assets
      		790,000 884,000                   
        promissory note receivable from related party
      		7,020,000 7,510,000                   
        other non-current assets
      		4,878,000 4,952,000                   
        deferred offering costs
      		                    
        total assets
      		152,976,000 160,878,000 126,166,000 130,838,000 141,510,000 148,988,000 157,485,000 172,782,000 192,092,000 215,335,000 171,764,000 152,401,000 172,259,000 190,468,000 211,184,000 227,747,000 247,879,000 261,705,000 278,827,000 293,662,000 
        liabilities, redeemable convertible preferred shares and stockholders’ equity
      		                    
        current liabilities:
      		                    
        accounts payable
      		1,439,000 2,081,000 512,000 805,000 897,000 1,540,000 1,408,000 1,909,000 2,066,000 3,950,000 1,772,000 2,759,000 2,093,000 2,361,000 4,092,000 2,388,000 2,384,000 1,928,000 2,474,000 2,528,000 
        accrued expenses and other current liabilities
      		7,533,000 6,902,000 2,978,000 4,096,000 6,097,000 3,777,000 3,093,000 4,817,000 8,581,000 11,193,000 6,455,000 5,424,000 8,343,000 8,677,000 5,348,000 4,331,000 5,854,000 4,232,000 3,771,000 3,564,000 
        deferred revenue, current
      		                    
        lease liabilities, current
      		2,262,000 2,161,000                   
        term loan
      		                    
        total current liabilities
      		11,234,000 11,144,000 7,324,000 8,793,000 10,778,000 9,240,000 8,196,000 10,169,000 14,205,000 19,271,000 12,008,000 13,950,000 21,503,000 25,040,000 28,514,000 25,331,000 27,189,000 30,572,000 30,543,000 30,015,000 
        non-current liabilities:
      		                    
        lease liabilities, non-current
      		713,000 1,284,000                   
        cvr liability due to related party
      		7,020,000 7,510,000                   
        other non-current liabilities
      		870,000 1,108,000                   
        total liabilities
      		19,837,000 21,046,000 10,259,000 12,588,000 15,576,000 14,756,000 14,626,000 17,435,000 22,335,000 28,146,000 15,064,000 17,379,000 25,290,000 31,680,000 36,816,000 34,792,000 40,002,000 58,442,000 62,567,000 66,018,000 
        commitments and contingencies
      		                    
        redeemable convertible preferred shares:
      		                    
        redeemable convertible preferred shares - 0.00005 par value; no shares and 2,905,696 shares authorized as of december 31, 2025 and december 31, 2024, respectively; no shares and 2,163,434 shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively; aggregate liquidation preference of 0 and 163,575 as of december 31, 2025 and december 31, 2024, respectively
      		                    
        total redeemable convertible preferred shares
      		                    
        stockholders’ equity
      		                    
        series a convertible preferred shares - 0.00005 par value; no shares authorized as of december 31, 2025 and 994,869 shares authorized, issued and outstanding as of december 31, 2024
      		                    
        preferred stock - 0.001 par value...
      		                    
        voting common stock - 0.001 par value...
      		11,000 11,000                   
        non-voting common stock - 0.001 par value...
      		                    
        additional paid-in capital
      		363,094,000 362,870,000 458,799,000 458,341,000 457,437,000 456,439,000 455,422,000 454,143,000 452,142,000 418,486,000 402,667,000 363,915,000 361,915,000 360,055,000 358,220,000 355,690,000 353,295,000 351,478,000 349,960,000 348,663,000 
        accumulated deficit
      		-230,053,000 -223,143,000 -343,005,000 -340,238,000 -331,619,000 -322,495,000 -312,261,000 -298,531,000 -282,385,000 -262,896,000 -245,553,000 -228,438,000 -214,219,000 -200,122,000 -182,784,000 -162,293,000 -145,454,000 -148,251,000 -133,736,000 -121,055,000 
        accumulated other comprehensive income
      		87,000 94,000 65,000 99,000 68,000 240,000               
        total stockholders’ equity
      		133,139,000 139,832,000 115,907,000 118,250,000 125,934,000 134,232,000 142,859,000 155,347,000 169,757,000 155,344,000 156,700,000 135,022,000 146,969,000 158,788,000 174,368,000 192,955,000 207,877,000 203,263,000 216,260,000 227,644,000 
        total liabilities, redeemable convertible preferred shares and stockholders’ equity
      		152,976,000 160,878,000                   
        redeemable convertible preferred shares - 0.00005 par value; no shares and 2,905,696 shares authorized as of september 30, 2025 and december 31, 2024, respectively; no shares and 2,163,434 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively; aggregate liquidation preference of 0 and 163,575 as of september 30, 2025 and december 31, 2024, respectively
      		                    
        series a convertible preferred shares - 0.00005 par value; no shares authorized as of september 30, 2025 and 994,869 shares authorized, issued and outstanding as of december 31, 2024
      		                    
        property and equipment
      		  419,000 506,000 593,000 682,000 772,000 864,000 2,335,000 2,633,000 2,875,000 3,126,000 3,205,000 3,115,000 2,950,000 2,292,000 2,439,000 2,125,000 2,102,000 2,118,000 
        right-of-use asset
      		  2,561,000 3,102,000 3,635,000 4,160,000 4,779,000 5,241,000 5,686,000 7,993,000 4,575,000 4,918,000 5,255,000 5,585,000 5,910,000 6,226,000 6,538,000 6,843,000 7,143,000 7,438,000 
        deposits and other assets
      		  24,173,000 10,231,000 10,113,000 2,613,000 2,613,000 5,511,000 5,409,000 4,075,000 3,668,000 3,179,000 3,789,000 3,790,000 3,179,000 3,179,000 2,386,000    
        liabilities and stockholders’ equity
      		                    
        operating lease liability
      		  3,834,000 3,892,000 3,784,000 3,923,000 3,695,000 3,443,000 3,558,000 3,469,000 1,937,000 1,920,000 1,907,000 1,894,000 1,880,000 1,863,000 1,851,000 1,838,000 1,826,000 1,584,000 
        long-term portion of operating lease liability
      		  1,843,000 2,718,000 3,737,000 4,471,000 5,397,000 6,302,000 7,180,000 8,023,000 3,056,000 3,429,000 3,787,000 4,138,000 4,483,000      
        other long-term liabilities
      		  1,092,000 1,077,000 1,061,000 1,045,000 1,033,000 964,000 950,000            
        stockholders’ equity:
      		                    
        preferred stock, 0.001 par value...
      		                    
        common stock, 0.001 par value...
      		  48,000 48,000 48,000 48,000 48,000 48,000 48,000    36,000 36,000 36,000 36,000 36,000 36,000 36,000 36,000 
        total liabilities and stockholders’ equity
      		  126,166,000 130,838,000 141,510,000 148,988,000 157,485,000 172,782,000 192,092,000  171,764,000 152,401,000 172,259,000 190,468,000 211,184,000 227,747,000     
        accumulated other comprehensive loss
      		      -350,000 -313,000 -48,000 -290,000 -456,000 -491,000 -763,000 -1,181,000 -1,104,000 -478,000     
        deferred revenue
      		         659,000 1,844,000 3,847,000 9,160,000 12,108,000 17,194,000 16,749,000 17,100,000 22,574,000 22,472,000 22,339,000 
        liabilities, convertible preferred stock and stockholders’ equity
      		                    
        other long term liabilities
      		         852,000           
        convertible preferred stock
      		                    
        series a non-voting convertible preferred stock, 0.001 par value -5,000,000 shares designated and 4,153,439 issued and outstanding as of september 30, 2023. no shares designated, issued and outstanding as of december 31, 2022
      		         31,845,000           
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 or december 31, 2022
      		                    
        common stock
      		         44,000 42,000 36,000         
        total liabilities, convertible preferred stock and stockholders’ equity
      		         215,335,000           
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 or december 31, 2022
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 or december 31, 2022
      		                    
        deferred revenue, net of current portion
      		             2,502,000 3,819,000 4,645,000 7,678,000 22,421,000 26,268,000 29,950,000 
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of december 31, 2022 and 2021; no shares issued and outstanding as of december 31, 2022 or december 31, 2021
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 or december 31, 2021
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 or december 31, 2021
      		                    
        long-term portion of lease liabilities
      		               4,816,000 5,135,000 5,449,000 5,756,000 6,053,000 
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 or december 31, 2021
      		                    
        liabilities, redeemable convertible preferred stock and stockholders’ equity
      		                    
        redeemable convertible preferred stock
      		                    
        stockholders’ deficit:
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of december 31, 2021 and no shares authorized as of december 31, 2020; no shares issued and outstanding as of december 31, 2021 or december 31, 2020
      		                    
        total liabilities, redeemable convertible preferred stock and stockholders’ equity
      		                247,879,000 261,705,000 278,827,000 293,662,000 
        other assets
      		                 872,000 872,000 872,000 
        preferred stock, 0.001 par value - 10,000,000 shares authorized as of september 30, 2021 and no shares authorized as of december 31, 2020; no shares issued and outstanding as of september 30, 2021 or december 31, 2020
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized at june 30, 2021 and no shares authorized at december 31, 2020; no shares issued and outstanding at june 30, 2021 or december 31, 2020
      		                    
        preferred stock, 0.001 par value - 10,000,000 shares authorized at march 31, 2021 and no shares authorized at december 31, 2020; no shares issued and outstanding at march 31, 2021 or december 31, 2020
      		                    
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
                            
          cash flows from operating activities:
        		                    
          net loss
        		-6,908,000    -9,124,000 -10,234,000   -19,489,000 -17,343,000 -17,115,000 -14,219,000 -14,097,000 -17,338,000 -20,491,000 -16,839,000 2,797,000 -14,515,000 -12,681,000 -9,716,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                    
          depreciation and amortization
        		393,000                    
          non-cash interest expense
        		0                    
          stock-based compensation expense
        		51,000 13,978,000 458,000 904,000                 
          accretion/amortization of premium/discount of available-for-sale securities
        		-38,000                    
          amortization of right of use-assets
        		168,000                    
          gain on early extinguishment of lease liability
        		0                    
          loss on disposal of property and equipment
        		    0 0 0 99,000 0 0   0 0       
          non-cash research and development expenses for the common stock issuable pursuant to hutchmed agreement
        		                    
          changes in operating assets and liabilities:
        		                    
          prepaid expenses and other current assets
        		-383,000 -2,986,000 -423,000 -165,000 717,000 212,000 -270,000 -269,000 564,000 932,000 31,000 308,000 554,000 2,718,000 -2,660,000 624,000 1,666,000 -1,259,000 -2,483,000 624,000 
          other non-current assets
        		72,000                    
          accounts payable
        		-641,000 -1,794,000 -293,000 -92,000 -643,000 132,000 -501,000 -157,000 -1,883,000 -666,000 -987,000 666,000 -85,000 -1,158,000 948,000 4,000 455,000 -546,000 404,000 48,000 
          accrued expenses and other current liabilities
        		848,000 -6,826,000 -1,118,000 -2,001,000 2,320,000 684,000 -1,724,000 -3,764,000 -2,352,000 -3,297,000 908,000 -2,919,000 -586,000 3,509,000 830,000 -1,523,000 1,695,000 475,000 938,000 -1,810,000 
          deferred revenue
        		0        -659,000 -1,185,000 -2,003,000 -5,313,000 -5,450,000 -6,403,000 -381,000 -3,384,000 -20,217,000 -3,745,000 -3,549,000 -3,474,000 
          operating lease liabilities
        		-544,000 1,150,000 -933,000 -911,000 -873,000 -698,000 -653,000 -993,000             
          other long-term liabilities
        		-236,000 -16,000 15,000 16,000 16,000 12,000 69,000 14,000             
          net cash from operating activities
        		-7,218,000 -26,642,000 -3,422,000 -10,562,000 -6,260,000 -8,938,000 -12,502,000 -18,304,000             
          capital expenditures
        		0 0 0 0 0 0 0              
          free cash flows
        		-7,218,000 -26,642,000 -3,422,000 -10,562,000 -6,260,000 -8,938,000 -12,502,000              
          cash flows from investing activities:
        		                    
          cash divested in non-ox40 divestiture
        		0                    
          proceeds from disposal of property and equipment
        		                    
          purchases of marketable securities
        		-8,913,000 21,699,000 -5,997,000 -17,187,000 -7,262,000 -8,771,000 -9,967,000 -62,298,000             
          maturities and sales of marketable securities
        		7,549,000                    
          net cash from investing activities
        		-1,364,000 -37,331,000 24,949,000 7,932,000 463,000 9,454,000 3,918,000 -48,738,000             
          cash flows from financing activities:
        		                    
          proceeds from term loan
        		0                    
          proceeds from exercise of stock options
        		0        0 15,000   1,000 24,000 575,000 495,000 236,000 69,000 35,000 242,000 
          issuance costs in connection with reverse recapitalization
        		0                    
          cash acquired in connection with reverse recapitalization
        		0                    
          proceeds from common stock issued in pipe financing, net of issuance costs
        		0                    
          net cash from financing activities
        		0                    
          effects of exchange rates on cash and cash equivalents
        		-48,000                    
          net increase in cash and cash equivalents
        		-8,630,000                    
          cash and cash equivalents, beginning of year
        		0                    
          cash and cash equivalents, end of year
        		-8,630,000                    
          supplemental disclosure of cash flow information:
        		                    
          cash paid for income taxes
        		9,000                    
          supplemental disclosure of non-cash investing and financing information:
        		                    
          accretion of redeemable convertible preferred shares
        		0                    
          deferred offering costs in accrued expenses and other current liabilities
        		                    
          exchange of preferred shares into common stock upon closing of reverse recapitalization
        		0                    
          forgiveness of term loan upon closing of reverse recapitalization
        		0                    
          reverse recapitalization issuance costs in accrued expenses
        		-221,000                    
          issuance of promissory note in connection with divesture
        		0                    
          net assets derecognized in connection with non-ox40 divestiture
        		0                    
          unrealized gain on marketable securities
        		                    
          right-of-use assets acquired by assuming operating lease liability
        		                    
          net income
        		  -2,767,000 -8,619,000    -16,146,000             
          adjustments to reconcile net income to net cash from operating activities:
        		                    
          depreciation
        		  87,000 87,000 89,000 90,000 92,000 219,000 305,000 242,000 242,000 231,000 210,000 213,000 148,000 180,000  147,000 145,000 89,000 
          net accretion of discounts on marketable securities
        		  -47,000 -196,000 -285,000 -366,000 -424,000 -393,000             
          non-cash operating lease expense
        		  541,000 533,000 525,000 619,000 462,000 445,000 562,000 471,000 344,000 337,000 330,000 325,000 316,000 312,000     
          impairment of assets held for sale
        		    0 0 0 742,000             
          deposits and other assets
        		  1,058,000 -118,000 0 -406,000 2,898,000 -102,000 -1,395,000 60,000   1,000 -611,000 0 -793,000     
          proceeds from sale of property and equipment
        		    0 190,000 185,000 60,000             
          proceeds from sales and maturities of marketable securities
        		                    
          amounts loaned under note receivable
        		                    
          net increase in cash, cash equivalents and restricted cash
        		    -5,797,000 516,000               
          cash, cash equivalents and restricted cash, beginning of period
        		  0 40,265,000 0 0 0 121,172,000  0 0 60,791,000  0 0 233,089,000  0 0 163,363,000 
          cash, cash equivalents and restricted cash, end of period
        		  21,527,000 37,635,000 -5,797,000 516,000 -8,584,000 54,130,000  50,815,000 41,539,000 30,201,000  18,587,000 1,610,000 47,749,000  -18,105,000 -17,006,000 281,882,000 
          reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets:
        		                    
          cash and cash equivalents
        		  21,527,000 36,763,000 -5,797,000 922,000 -8,584,000 52,852,000 -1,383,000 50,409,000 41,539,000 29,329,000 -7,155,000 18,587,000 1,610,000 46,877,000 -13,682,000 -18,105,000 -17,006,000 281,010,000 
          restricted cash included in deposits and other assets
        		  0 872,000                 
          options to purchase common stock
        		  -206,783,000 6,539,639,000    8,696,192,000             
          total
        		  -206,783,000 6,539,639,000    8,696,192,000             
          proceeds from maturities of marketable securities
        		   25,119,000 15,225,000 18,035,000 13,700,000 13,500,000             
          net decrease in cash, cash equivalents and restricted cash
        		   -2,630,000    -67,042,000             
          impairment of right-of-use asset
        		                    
          purchases of property and equipment
        		        -262,000 0 0 -152,000 -231,000 -1,131,000 -36,000 -33,000  -184,000 -187,000 -839,000 
          cash and cash equivalents acquired in connection with the acquisition of pionyr, net of issuance costs paid
        		        60,000            
          cash consideration paid in connection with the acquisition of pionyr
        		        0            
          proceeds from issuance of common stock for underwritten registered offering, net of offering costs
        		        0 -123,000           
          repurchase of common stock
        		        0 0           
          reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
        		                    
          stock-based compensation
        		     1,017,000 1,279,000 2,001,000  1,998,000 1,879,000 2,000,000  1,811,000 1,955,000 1,900,000 1,581,000 1,449,000 1,262,000 885,000 
          restricted cash included in other assets
        		     -406,000 0 1,278,000 0 406,000 0 872,000 0 0 0 872,000 0 0 0 872,000 
          adjustments to reconcile net income to net cash from operating activities
        		                    
          cash flows from operating activities
        		                    
          adjustments to reconcile net loss to net cash from operating activities
        		                    
          amortization of marketable securities
        		            -53,000 34,000 27,000 42,000     
          impairment of right of use asset
        		                    
          net realized loss on marketable securities
        		            0        
          changes in operating assets and liabilities
        		                    
          lease liability
        		        -754,000 -632,000 -356,000 -345,000 -338,000 -331,000 -316,000 -307,000 -300,000 -296,000 -55,000 -89,000 
          net cash flows from operating activities
        		        -21,819,000 -19,997,000 -18,143,000 -19,784,000 -17,655,000 -17,219,000 -19,451,000 -19,784,000 -13,368,000 -17,990,000 -15,724,000 -13,170,000 
          cash flows from investing activities
        		                    
          sales and maturities of marketable securities
        		        45,477,000 50,061,000 28,000,000 31,072,000 37,205,000 51,780,000       
          net cash flows from investing activities
        		        20,376,000 31,894,000 22,680,000 -10,806,000 10,499,000 35,782,000 20,486,000 -166,051,000 -550,000 -184,000 -187,000 -839,000 
          cash flows from financing activities
        		                    
          net cash flows from financing activities
        		        60,000 38,918,000   1,000 24,000 575,000 495,000 236,000 69,000 -1,095,000 132,528,000 
          cash, cash equivalents and restricted cash, beginning of year
        		                    
          cash, cash equivalents and restricted cash, end of year
        		                    
          reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
        		                    
          supplemental disclosure of non-cash activities
        		                    
          right-of-use asset recognized upon assumption of san francisco, ca lease from pionyr
        		                    
          purchases of property and equipment in accounts payable and accrued expenses
        		            69,000 -753,000       
          amortization of premiums and discounts on marketable securities
        		         -577,000 -602,000 -530,000         
          sale of property and equipment
        		         0           
          purchase of marketable securities
        		         -18,167,000 -5,324,000 -41,726,000 -26,475,000 -14,867,000 -8,978,000 -166,018,000     
          net increase in cash and cash equivalents and restricted cash
        		         50,815,000 41,539,000 -30,590,000  18,587,000 1,610,000 -185,340,000  -18,105,000 -17,006,000 118,519,000 
          reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
        		                    
          supplemental cash flow information
        		                    
          noncash investing and financing activities
        		                    
          underwritten registered offering costs in accrued expenses
        		                    
          reclassification of deposits and other assets to prepaid expenses and other current assets
        		           609,866,000         
          unrealized gains on marketable securities
        		           272,000         
          adjustments to reconcile net loss to net cash from provided by operating activities
        		                    
          proceeds from initial public offering, net of offering costs
        		                0 0 -1,130,000 132,432,000 
          proceeds from issuance of preferred stock, net of offering costs
        		                    
          right-of-use assets and lease liabilities recognized upon lease inception
        		                0 0 0 7,541,000 
          payment of preferred issuance costs
        		                 0 0 -146,000 
          purchases of property and equipment in accrued expense
        		                 -14,000 -57,000 157,000 
          deferred transaction costs in accounts payable and accrued expenses
        		                   1,130,000 
          depreciation expense
        		                    
          non-cash research and development expense for in-process research and development acquired in acquisition
        		                    
          non-cash lease expense
        		                   273,000 
          cash obtained in asset acquisition
        		                    
          payments to acquire property and equipment
        		                    
          assets obtained in asset acquisition
        		                    
          liabilities assumed in asset acquisition
        		                    
          fair value of equity instruments issued in connection with asset acquisition
        		                    
          deferred transaction costs in accounts payable and accrued liabilities
        		                    
          right-of-use assets recognized upon adoption of asc 842
        		                    
          right-of-use asset obtained in exchange for operating lease liability
        		                    
          right-of-use amortization